मैट्रिक्स
 
 
इंड-स्विफ्ट > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का इंड-स्विफ्ट - बीएसई: 524652, NSE: INDSWFTLTD

इंड-स्विफ्ट

बीएसई: 524652  |  NSE: INDSWFTLTD  |  ISIN: INE788B01028  |  Pharmaceuticals

कंपनी इतिहास - इंड-स्विफ्ट
Ind-Swift Ltd. is an existing profit making, dividend paying company
 engaged in fromulation of injectables and opthalmic products at
 Panchkula, Dist. Ambala (Haryana). It was incorporated as a limited
 company on 06.06.1986 and was granted certificate of commencement of
 business on 15.12.1986. In July'89 the Company got its project for
 manufacture of injectables and trading of pharmaceutical products
 appraised from Haryana Financial Corporation (HFC) which was
 implemented in December'90 for a total cost of 49.77 lakhs.
 
 The company has been promoted by Shri Anil Kumar Jain, Shri Sanjiv
 Rai Mehta, Dr. Gopal Munjal & Associates.
 
 The company is expanding its activities by setting up facilities for
 manufacture of formulation (tablets and capsules).
 
 
 
 2000 - Ind Swift Ltd, a Chandigarh-based pharmaceutical company, has
 set up a unique 
              R&D centre having facilities for bio-equivalence
 studies, clinical trials for Ist, IInd 
              and IIIrd phase, and toxicologial studies.
 
 2001 - The Company has launched two new divisions, Super Speciality
 Division and Healthcare
               Division.  These divisions have launched 20 products in
 the fastest growing segments
               viz. Diabetology, Neurology, Cardiology, Anti-AIDS,
 Anti-Viral, etc.
 
 2002-Ind Swift Ltd has informed that it has restructured its Board by
 inducting three professional Directors on its Board. The three new
 Directors are Dr R S Bedi, Dr J K Kakkar & Mr K M S Nambiar. The
 Company's Board is gradually shifting from a closely held Board to
 professionally held Board.
 
 2003
 
 -High Court appoves the scheme of amalgamation of Swift Formulation
 Pvt Ltd and Mukur Pharmaceutical Company Pvt Ltd with Ind Swift Ltd.
 
 - Allottement of  1227375 equity shares to Promoters & other Bodies
 corporates upon the conversion of their preference shares into equity
 shares.
 
 -Out come of board meeting
 Issuance of GDRs aggregating upto US $ 20 million 
 Preferential issue of upto 1.6 million equity shares at a premium of
 Rs 80 per share to the promoters as well as other investors
 Issuance of 350000 zero coupon fully convertible warrants to the
 promoters 
 Increase in Authorised share capital of the company from Rs 100
 million to Rs 150 million 
 Delisting of equity shares from Ahmedabad, Delhi & Jaipur Stock
 Exchanges
 
 2004
 
 - Allotment of 3,50,000 zero coupon warrants to the promoters of the
 company convertible into 
 equity shares on or before March 31, 2004.
 
 - Allotment of 12,50,000 zero coupon warrants to the bodies corporate
 convertible into equity shares on or before March 31, 2004.
 
 - Allotment of 3,50,000 zero coupon warrants to the promoters of the
 company convertible into equity shares at any time within 18 months
 but not before April 1, 2004.
 
 - Ind Swift Ltd ties up with Lupin Ltd for a Co-marketing pact to
 launch Nitazoxanide, an anti-diarrhoeal / anti-helmintic drug for the
 first time in India under the brand name Netazox and Nizonide
 respectively
 
 -Ind-Swift Laboratories Ltd. has informed that their Company has been
 awarded the achievement award for the Best Performing Company in
 Category E by the Express Pharma Pulse for the year 2004
 
 -Ind Swift Ltd has informed that the Company has launches a new
 Marketing Division under the name 'Resurgence' for Anesthesiology,
 Oncology and Surgery Segment
 
 -Ind Swift launches Novel Drug Delivery of Nitazoxanide
 
 -Company has splits its Face value of Shares from Rs 10 to Rs 2
 
 2010
 
 - Ind-Swift Limited has informed vide its letter dated March 23, 2010
 that:Pursuant to the provisions of Section 260 of The Companies Act,
 1956 and Articles of Association of the company, Mr. Rishav Mehta has
 been appointed as Additional Director of the company.
 
 - Ind-Swift Ltd has informed that pursuant to the provisions of
 Section 260 of The
Companies Act, 1956 and Articles of Association of the Company, Mr. Rishav Mehta has been appointed as Additional Director of the Company. 2012 - ROCHE DIAGNOSTICS enters into agreement with ISL to expand TROP T Rapid assay adoption in India. - Ind-Swift in Collaboration with Wockhardt UK Limited Launches Atorvastatin Tablets in UK. - Ind Swift Labs today said it has bagged its first contract research order from a European pharmaceutical firm. 2014 - Ind-Swift Ltd has appointed Mr. V. K. Arora as an Additional Director (Non Executive, Non Promoter- independent) on the Board of Directors of the Company.
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • JEFFERIES ON MGL : BUY रेटिंग, लक्ष्य घटाकर `1180/Sh
  • CITI ON NMDC : BUY रेटिंग, लक्ष्य `125/Sh
  • MS ON ADANI PORTS : Overweight रेटिंग, लक्ष्य `408/Sh
  • CITI ON COAL INDIA : BUY रेटिंग, लक्ष्य बढ़ाकर `270/Sh
  • CITI ON MOTHERSON SUMI : Neutral रेटिंग, लक्ष्य बढ़ाकर `135/Sh
  • CITI ON BRITANNIA IND : BUY रेटिंग, लक्ष्य बढ़ाकर `3575/Sh
  • CITI ON INDIAN ECONOMY : Q2 में GDP ग्रोथ 4.9% रहने का अनुमान
  • CITI ON INDIAN ECONOMY : Q3 में ग्रोथ 6% के करीब रहने का अनुमान
  • HSBC ON IIP : IIP पर दबाव की स्थिति बरकरार
  • HSBC ON IIP : कैपिटल गुड्स में लगातार 5वें महीने गिरावट

अभी देखें

स्टॉक 20-20

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.